Welcome to our dedicated page for Milestone Pharmaceuticals Common Shares news (Ticker: MIST), a resource for investors and traders seeking the latest updates and insights on Milestone Pharmaceuticals Common Shares stock.
Milestone Pharmaceuticals Inc. (Symbol: MIST) is a biopharmaceutical company headquartered at 6100 Royalmount Ave, Montreal, QC, Canada. The company specializes in developing and commercializing innovative treatments for cardiovascular conditions, with a key focus on its lead investigational product, etripamil.
Milestone's primary product, etripamil, is a calcium channel blocker designed for rapid onset as a nasal spray. This unique formulation allows patients to self-administer the medication to terminate episodes of paroxysmal supraventricular tachycardia (PSVT). PSVT is a condition characterized by an abnormally fast heart rate, which can be both sudden and recurrent.
The company is also conducting a Phase 2 clinical trial to evaluate the efficacy of etripamil for patients with atrial fibrillation experiencing a rapid ventricular rate (AFib-RVR). This trial marks another significant step in expanding the usage of etripamil to address additional cardiovascular indications.
Recent Achievements and Current Projects:
- Milestone intends to use the proceeds from its latest offering to further the development of etripamil for PSVT and AFib-RVR, along with other general corporate purposes.
- The company has secured a shelf registration statement on Form S-3, effective as of February 2, 2022, allowing for streamlined securities offering.
- Milestone actively participates in educational initiatives, such as partnering with the Arrhythmia Alliance for SVT Awareness Day, aimed at raising awareness about heart rhythm disorders.
Financial Condition and Partnerships: Milestone maintains a strong financial position, supported by recent offerings and strategic partnerships. The company's collaborations with healthcare organizations and participation in global awareness campaigns underline its commitment to improving cardiovascular health.
Key Highlights:
- Innovative treatment for PSVT with a patient-administered nasal spray.
- Ongoing Phase 2 trial for AFib-RVR.
- Effective use of proceeds for development and expansion.
- Active involvement in cardiovascular health awareness initiatives.
With a robust pipeline and strategic initiatives, Milestone Pharmaceuticals Inc. is dedicated to addressing unmet needs in cardiovascular care, making significant strides in the biopharmaceutical industry.
Milestone Pharmaceuticals (MIST) reported Q2 2021 financial results, highlighting a revenue of $15 million from an exclusive license agreement. As of June 30, the company had $135.8 million in cash and investments. Operating income reached $0.7 million, a significant improvement from a loss of $13.1 million in Q2 2020. Progress continues in clinical trials for etripamil, with increasing enrollment rates for the Phase 3 RAPID trial and positive potential indicated for AFib-RVR treatment. The company remains on track to report topline data in H2 2022.
Milestone Pharmaceuticals (Nasdaq: MIST) announced that Joseph Oliveto, President and CEO, will present at the Jefferies Virtual Healthcare Conference on June 2, 2021, at 4:00 PM ET. The event will be held virtually, and a live webcast can be accessed on Milestone's website, with an archived replay available afterward. Milestone focuses on innovative cardiovascular medicines, with its lead product candidate, etripamil, in Phase 3 trials for paroxysmal supraventricular tachycardia and Phase 2 for atrial fibrillation. For more details, visit www.milestonepharma.com.
Milestone Pharmaceuticals (Nasdaq: MIST) announced significant data from its NODE-301 trial of etripamil, a novel nasal spray for treating paroxysmal supraventricular tachycardia (PSVT). Data presented at the American College of Cardiology's 70th Annual Scientific Session revealed that etripamil showed statistically significant improvements in symptoms and reduced emergency room visits compared to placebo. The trial enrolled 431 patients, showing a 51% reduction in ER visits and marked improvements in treatment satisfaction metrics. Milestone is also progressing with its pivotal RAPID trial for etripamil.
Milestone Pharmaceuticals (MIST) reported Q1 2021 financial results, highlighting cash reserves of $129.9 million. The pivotal Phase 3 RAPID trial of etripamil is ongoing, with topline data expected in H2 2022. An exclusive license agreement with Ji Xing Pharmaceuticals will advance etripamil in Greater China, providing an upfront $15 million and potential milestone payments up to $107.5 million. R&D expense decreased to $8.6 million amid COVID-19 disruptions, with operating loss reduced to $12.6 million from $16.8 million year-over-year.
Milestone Pharmaceuticals (Nasdaq: MIST) announced a collaboration with Ji Xing Pharmaceuticals to develop and commercialize etripamil for paroxysmal supraventricular tachycardia (PSVT) in Greater China. The agreement includes a $15 million upfront payment, a $5 million equity investment, and potential milestone payments of up to $107.5 million. Etripamil, designed as a rapid-response therapy for PSVT, aims to transform treatment from emergency settings to home use. Ongoing Phase 3 trials for PSVT and a Phase 2 trial for atrial fibrillation are part of Milestone's comprehensive development program.
Milestone Pharmaceuticals (MIST) reported its financial results for Q4 and the full year of 2020, emphasizing progress in its etripamil development program for PSVT. The company has $142.3 million in cash, showing growth from $119.8 million in 2019. R&D expenses decreased to $5.8 million in Q4 from $14.1 million in the same period last year, aiding in narrowing the operating loss to $8.8 million. Milestone remains on track for topline data from the Phase 3 RAPID trial in late 2021 or early 2022 and has initiated a Phase 2 study for atrial fibrillation patients.
Milestone Pharmaceuticals Inc. (Nasdaq: MIST) has enrolled the first patient in its Phase 2 proof-of-concept study, known as the ReVeRA study, for etripamil nasal spray aimed at reducing ventricular rate in patients with atrial fibrillation and rapid ventricular rate (AFib-RVR). This double-blind, placebo-controlled trial in Canada will involve 50 participants, assessing both safety and efficacy. Currently, AFib impacts approximately 5 million Americans, projected to rise to 12 million in the next decade, presenting a significant market opportunity for etripamil if successful.
Milestone Pharmaceuticals Inc. (Nasdaq: MIST) announced that CEO Joseph Oliveto will present at several upcoming investor conferences. Key events include the Cowen 41st Annual Health Care Conference on March 4, 2021, the H.C. Wainwright Global Life Sciences Conference on March 9, 2021, and the Oppenheimer 31st Annual Healthcare Conference on March 16, 2021. A replay of the H.C. Wainwright presentation and a live webcast of the Oppenheimer presentation will be available on their website. Milestone focuses on developing etripamil for cardiovascular treatment.
Milestone Pharmaceuticals (Nasdaq: MIST) has announced that its President and CEO, Joseph Oliveto, will present at two upcoming investor conferences. The events include the Piper Sandler 32nd Virtual Annual Healthcare Conference and the Evercore ISI 3rd Annual HealthCONx Conference on December 3, 2020, at 4:20 p.m. ET. A replay of the Piper Sandler fireside chat is available on the company's website, along with a live webcast of the Evercore presentation. Milestone is focused on developing etripamil for cardiovascular treatments.
Milestone Pharmaceuticals announced the enrollment of the first patient in the RAPID Phase 3 trial for etripamil, a treatment for paroxysmal supraventricular tachycardia (PSVT). The trial aims to assess the efficacy of a second dose of etripamil in patients who do not achieve symptom relief within 10 minutes. With a target of 500 patients and 180 confirmed SVT events, the data is expected by late 2021/early 2022. This trial follows the NODE-301 trial, which showed promising safety and efficacy results. Success in RAPID could support future FDA approvals for etripamil.
FAQ
What is the current stock price of Milestone Pharmaceuticals Common Shares (MIST)?
What is the market cap of Milestone Pharmaceuticals Common Shares (MIST)?
What does Milestone Pharmaceuticals Inc. specialize in?
What is etripamil?
What is PSVT?
What are Milestone's recent achievements?
How is Milestone Pharmaceuticals funded?
What is the significance of Milestone's partnership with Arrhythmia Alliance?
Where is Milestone Pharmaceuticals located?
What are the future plans for etripamil?
How can I obtain the latest financial reports for Milestone?
What are the risks associated with Milestone's forward-looking statements?
